Strides Pharma acquires Amexel Pte. Ltd. in Singapore

Strides Pharma Science Limited announced its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited ("SPG"), will acquire 100% stake in Amexel Pte. Ltd., Singapore for a nominal cash consideration of $10 USD. Amexel, incorporated in Singapore in March 2023, is currently non-operational. As a wholly-owned subsidiary of SPG, Amexel will focus on in-licensing technologies, sourcing, and building partnerships to support the supply, distribution, and commercialization of pharmaceutical products in various territories. Strides Pharma aims to create a platform that fosters collaborations and procurement between pharmaceutical manufacturers and suppliers of India, China, and Southeast-Asian countries through Amexel. The acquisition is expected to be completed by March 31, 2025.